PFE
Pfizer Inc
Healthcare, Event Driven/Special Sit
10/21/2015
Presented
| Date | 10/16/2015 |
| Price | $34.41 |
| Market Cap | $214.82B |
| Ent Value | $216.94B |
| P/E Ratio | 24.38x |
| Book Value | $10.84 |
| Div Yield | 0% |
| Shares O/S | 6,243.00M |
| Ave Daily Vol | 26,302,718 |
| Short Int | 1.18% |
Current
| Price | $29.44 |
| Market Cap | $166.83B |
| Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer healthcare products. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. It operates its business through three operating segments: the Global Innovative Pharmaceutical, the Global Vaccines, Oncology and Consumer Healthcare, and the Global Established Pharmaceutical. The Global Innovative Pharmaceutical segment is focused on developing, registering and commercializing novel, value creating medicines that significantly improve patients lives. The Global Vaccines, Oncology and Consumer Healthcare segment focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. The Global Established Pharmaceutical segment includes the brands that have lost market exclusivity and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets and, to a much smaller extent, generic pharmaceuticals. Pfizer was founded by Charles Pfizer Sr. and Charles H. Erhart Jr. in 1849 and is headquartered in New York, NY. |
Publicly traded companies mentioned herein: Pfizer (PFE), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bayer (BAY GR), Sanofi (SNY), Allergan (AGN) and Teva (TEVA)
Highlights
The presenter sees Pfizer as a victim of market apathy. The company has earned a steady but uninspiring $2.20 per share annually for the past decade or so, aided in part by PFE’s steady use of the balance sheet to boost earnings. The company reports in three segments: global innovative pharma; global established pharma; and vaccines, oncology and consumer healthcare (VOC). Although Pfizer recently closed the Hospira deal, which will become part of its global established pharma unit, management has long discussed a potential break up of the company. The presenter expects that the company will likely come to a decision on a possible break up by mid to late next year, with a possible deal consummated by the end of 2017. Additionally, Pfizer has only recently gained traction in immuno oncology on the strength of its new drug, Ibrance. Yielding over 3 percent, he believes that the stock could be worth $42.50 per share on a sum of the parts basis.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.